| Literature DB >> 31027301 |
Po-Wen Ku1,2, Andrew Steptoe3, Yung Liao4, Ming-Chun Hsueh5, Li-Jung Chen6.
Abstract
Background: This meta-analysis aimed to estimate the shape of the dose-response association between objectively-assessed daily sedentary time (ST) and all-cause mortality, and to explore whether there is a threshold of ST above which there is an increase in mortality risk in older adults.Entities:
Keywords: cut-point; inactivity; meta-analysis; recommendation; review; sedentary behavior; sitting
Year: 2019 PMID: 31027301 PMCID: PMC6517908 DOI: 10.3390/jcm8040564
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1PRISMA diagram showing study selection.
Characteristics of studies.
| Author (Year), Country | Study Population | Follow-Up Years Mean | ST Measure (Mean or Median Time) | Covariates (Number of Covariates) | Cut-off (h/d) | Cox Regression HR (95% CIs) | Quality | ||
|---|---|---|---|---|---|---|---|---|---|
| Age Mean (±SD) | Male (%) | ||||||||
| Koster et al., 2012, USA [ | 1091 (126) | ≥65 | 68.8% | 2.8 y | Objectively measured SB < 100 counts/1 min [AM-7164 ActiGraph] (ST median: male = 9.18, female = 8.68 h) | Age, sex, race/ethnicity, education, BMI, diabetes, coronary heart disease, congestive heart failure, cancer, stroke, mobility limitation, smoking, alcohol, MVPA, accelerometer wear time (15) | Quartile: male/female | 1.0 | |
| <7.6/<7.2 (ref.) | 1.00 | ||||||||
| >7.6–≤9.18/ | 1.55 (0.44–5.54) | ||||||||
| >9.18–≤10.75/ | 3.13 (1.17–8.39) * | ||||||||
| >10.75/>10.09 | 4.18 (1.70–10.31) * | ||||||||
| Ensrud et al., 2014, USA [ | 2918 (409) | ≥71 | 100% | 4.5 y | Objectively measured SB ≤ 1.50 METs [sensewear pro armband] | Age, sex, race, education, marital status, site, season, health status, comorbidity burden, depressive symptoms, cognitive function, body fat %, number of instrumental activity of daily living impairments, smoking, sleep time, gait speed, self-reported total PA (17) ¶ | ≤12.86 (ref.) | 1.00 † | 0.95 |
| 12.87–14.08 | 1.30 (0.93–1.81) | ||||||||
| 14.09–15.24 | 1.19 (0.83–1.70) | ||||||||
| >15.24 | 1.79 (1.19–2.70) * | ||||||||
| § Fox et al., 2015, UK [ | 208 | ≥70 | 51.2% | 4.3 y | Objectively measured SB < 100 counts/1 min | Age, sex, educational, index of multiple deprivation, weight status, general practitioner system, number of self-reported chronic illnesses at baseline, lower limb function (9) ¶; Re-analysis further including MVPA & accelerometer wear time = 11) | <10.55 (ref.) | 1.00 | 1.0 |
| ≥10.55–11.59 | 1.01 (0.39–2.56) | ||||||||
| ≥11.6 | 0.99 (0.34–2.86) | ||||||||
| Schmid et al., 2015, USA [ | 1677 (112) | ≥50 | 49% | 2.9 y | Objectively measured SB < 100 counts/1 min [AM-7164 ActiGraph] | Age, sex, education, ethnicity, history of diabetes, cardiovascular disease, cancer, mobility limitations, BMI, smoking, alcohol, light PA, MVPA (13) ¶ | <8.60 (ref.) | 1.00 | 0.95 |
| ≥8.60 | 1.59 (0.84–3.03) †† | ||||||||
| Lee, 2016, USA [ | 1768 (453) | ≥65 | 51.8% | 6.3 y | Objectively measured SB < 100 counts/1 min [AM-7164 ActiGraph] | Age, sex, education, income, BMI, self-reported general health, condition, high blood pressure, high cholesterol, type 2 diabetes, history of heart attack, stroke, cancer, energy intake by 24-h dietary recall, binge drinking, smoking, MVPA, accelerometer wear time (18) | Quartile | 1.0 | |
| ≥4.6–<8.8 (ref.) | 1.00 | ||||||||
| ≥8.8–<10.0 | 1.28 (0.82–1.99) | ||||||||
| ≥10.0–<11.6 | 1.36 (0.89–2.09) | ||||||||
| ≥11.6–<20.8 | 1.87 (1.22–2.86) * | ||||||||
| Klenk et al., 2016, Southern Germany [ | 1271 | ≥65 | 46.4% | 4 y | Objectively measured lying or sitting activPAL | Age, sex, education, BMI, diabetes, hypertension, cardiovascular disease, cancer, chronic kidney disease, blood glucose. smoking, alcohol, walking time (which includes light, moderate and vigorous intensity physical activity) (13) ¶ | 5.85–<10.4 (ref.) | 1.00 | 0.95 |
| ≥10.4–<11.75 | 1.10 (0.54–2.24) | ||||||||
| ≥11.75–<12.94 | 0.65 (0.31–1.35) | ||||||||
| ≥12.94–<17.21 | 1.62 (0.85–3.07) | ||||||||
| Diaz et al., 2017, USA [ | 7985 | ≥45 | 45.8% | 4 y | Objectively measured SB < 50 counts/1 min [Actical-Philips Respironics] | Age, sex, race, region of residence, education, season, BMI, diabetes, hypertension, dyslipidemia, estimated glomerular filtration rate < 60 mL/min/1.73 m2, atrial fibrillation, history of coronary heart disease, stroke, smoking, alcohol, MVPA, standardized 16 h of accelerometer wear (18) | <11.50 (ref.) | 1.00 † | 1.0 |
| ≥11.50–<12.44 | 1.22 (0.74–2.02) | ||||||||
| ≥12.44–<13.32 | 1.61 (0.99–2.63) | ||||||||
| ≥13.32 | 2.63 (1.60–4.30) * | ||||||||
| Dohrn et al., 2017, Sweden [ | 851 | ≥35 | 44.1% | 14.2 y | Objectively measured SB < 100 counts/1 min [AM-7164ActiGraph] | Age, sex, education, hypertension, heart disease, cancer, diabetes, BMI, smoking, MVPA, accelerometer wear time (11) | 6.55–<8.20 (ref.) | 1.00 | 1.0 |
| 8.20–<9.83 | 1.88 (0.99–3.55) | ||||||||
| ≥9.83 | 2.72 (1.40–5.30) * | ||||||||
| Koolhaas et al., 2017, The Netherlands [ | 650 | 65–98 | 47.4% | 11 y | Objectively measured SB ≤ 199 counts/1 min [Actiwatch model AW4] | Age, sex, education, number of comorbidities, the 24 h activity rhythm, activities of daily living score, smoking, alcohol, MVPA, cohort and time awake (10) | <8 (ref.) | 1.00 | 0.95 |
| 8–<11 | 1.21 (0.71–2.04) | ||||||||
| ≥11 | 1.58 (0.87–2.88) | ||||||||
| Jefferis et al., 2018, UK [ | 1181 | 71–92 | 100% | 5.0 y | Objectively measured SB < 100 counts/1 min [ActiGraph GT3X] | Age, sex, region of residence, living alone, season of wear, social class, BMI, mobility disability, alcohol, smoking, sleep time, MVPA, accelerometer wear time (13) | 4.9–<9.3 (ref.) | 1.00 | 1.0 |
| ≥9.3–<10.3 | 1.14 (0.69–1.91) | ||||||||
| ≥10.3–<11.2 | 1.55 (0.91–2.64) | ||||||||
| ≥11.2–<17.6 | 2.73 (1.50–4.95) * | ||||||||
| Lee et al., 2018, USA [ | 16,741 | 0% | 2.3 y | Objectively measured SB < 200 counts/1 min [ActiGraph Corp] | Age, sex, hormone therapy, parental history of myocardial infarction, family history of cancer, general health, cardiovascular disease, cancer, cancer screening, smoking, alcohol, intakes of saturated fat/fiber/fruits/ vegetables, MVPA, accelerometer wear time (14) | <7.24 (ref.) | 1.00 | 1.0 | |
| ≥7.24–<8.38 | 0.97 (0.62–1.50) | ||||||||
| ≥8.38–<9.51 | 1.18 (0.77–1.82) | ||||||||
| ≥9.51 | 0.92 (0.56–1.50) | ||||||||
| Average of total | Total sample | Total weighted average of ST = 10.08 h | |||||||
* p < 0.05; p for trend. †: significant (p < 0.05); ‡: Two studies did not report mean age of the study samples. The mean age of these studies was recalculated as follows: ∑ (median age of an age group) × (sample size of a age group) divided by the total sample size [11,14]. a: One study reported mean age but did not provide SD of sample age [21]; §: After further adjusting MVPA and accelerometer wearing, the HRs (95% CI) for Fox’s study were recalculated as follows: <10.55 h: 1.00 (ref.); 10.55–11.59 h: 1.16 (0.37–3.65); ≥11.6 h: 2.00 (0.53–7.58); ¶: covariates without including MVPA or accelerometer wear time; ††: The results excluding deaths that occurred during the first year of follow up. Abbreviations: BMI, body mass index; M, mean; y, years; HR, hazard ratio; CIs, confidence intervals; h/d, hour/day; PA, physical activity; MVPA, moderate to vigorous physical activity; SD, standard deviation; ST, sedentary time.
Dose-response relationships of objectively-measured sedentary time with all-cause mortality assessed using random-effects meta-regression models.
| Models | Number of ES | Coefficients (SE) | t | |
|---|---|---|---|---|
| Model 1 | 31 | |||
| Sedentary time | 0.04 (0.03) | 1.49 | 0.15 | |
| Model 2 | 24 | |||
| Sedentary time | 0.08 (0.03) | 2.49 | 0.02 | |
| Model 3 | 24 | |||
| Sedentary time | 0.10 (0.03) | 3.65 | 0.002 | |
| Sample size ( | −0.43 (0.14) | −3.16 | 0.01 | |
| Model 4 (sensitivity analysis 1) | 31 | |||
| Sedentary time | 0.04 (0.02) | 1.91 | 0.07 | |
| Model 5 (sensitivity analysis 2) | 24 | |||
| Sedentary time | 0.08 (0.03) | 3.12 | 0.01 | |
| Model 6 (sensitivity analysis 3) | 24 | |||
| Sedentary time | 0.09 (0.02) | 3.84 | 0.001 | |
| Sample size ( | −0.41 (0.14) | −2.96 | 0.01 |
ES, effect size; SE, standard error. t: Knapp-Hartung method; Models 2 and 3 and Models 5 and 6, excluding studies without adjustment for accelerometer wear time.
Figure 2Scatter plots of meta-regression for Model 1 (A) based on all studies and 2 (B) excluding studies without adjustment for accelerometer wear time).
Figure 3Meta-regression of all-cause mortality risk associated with daily ST based on Model 3.
Figure 4Funnel plot with imputed studies.